Cargando…

Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis

Despite COVID-19’s significant morbidity and mortality, considering cost-effectiveness of pharmacologic treatment strategies for hospitalized patients remains critical to support healthcare resource decisions within budgetary constraints. As such, we calculated the cost-effectiveness of using remdes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Congly, Stephen E., Varughese, Rhea A., Brown, Crystal E., Clement, Fiona M., Saxinger, Lynora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423816/ https://www.ncbi.nlm.nih.gov/pubmed/34493774 http://dx.doi.org/10.1038/s41598-021-97259-7

Ejemplares similares

430 Patients with Prolonged (>10 days) Neutropenia Displayed Similar IFI Rates Regardless of Hematologic Diagnosis and Chemotherapy Status: A Challenge to Antifungal Prophylaxis Decisions
por: Saxinger, Lynora, et al.
Publicado: (2014)

Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis
por: Turvey, Shannon L., et al.
Publicado: (2022)

Informing COVID-19 vaccination priorities based on the prevalence of risk factors among adults in Canada
por: McAlister, Finlay A., et al.
Publicado: (2021)

Établir les priorités de la vaccination contre la COVID-19 en fonction de la prévalence des facteurs de risque chez les adultes au Canada
por: McAlister, Finlay A., et al.
Publicado: (2021)

Rotating opportunistic prevalence audit: A new pragmatic audit method is effective at identifying misuse of ciprofloxacin in a large academic hospital
por: Chen, Justin Z., et al.
Publicado: (2023)

Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?
por: Patel, Devangi, et al.
Publicado: (2023)

1722. Histoplasmosis Acquired in Alberta, Canada, 2011–2018
por: Dingle, Tanis, et al.
Publicado: (2019)

A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
por: Colombo, Giorgio L, et al.
Publicado: (2009)

The impact of shifting demographics, variants of concern and vaccination on outcomes during the first 3 COVID-19 waves in Alberta and Ontario: a retrospective cohort study
por: McAlister, Finlay A., et al.
Publicado: (2022)

One Health Evaluation of Antimicrobial Use and Resistance Surveillance: A Novel Tool for Evaluating Integrated, One Health Antimicrobial Resistance and Antimicrobial Use Surveillance Programs
por: Haworth-Brockman, Margaret, et al.
Publicado: (2021)

Integrated surveillance of antimicrobial resistance and antimicrobial use: Evaluation of the status in Canada (2014–2019)
por: Otto, Simon J. G., et al.
Publicado: (2022)

Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting
por: Congly, Stephen E., et al.
Publicado: (2021)

Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma
por: Buendía, Jefferson Antonio, et al.
Publicado: (2021)

Intermittent Proton Pump Inhibitor Therapy in Low-Risk Non-Variceal Upper Gastrointestinal Bleeding May Be Significantly Cost-Saving
por: Lei, Yang, et al.
Publicado: (2023)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndrome
por: Voigt, Jeffrey
Publicado: (2020)

Use of facemasks during the COVID-19 pandemic
por: Schünemann, Holger J, et al.
Publicado: (2020)

Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
por: Zhou, Ting, et al.
Publicado: (2021)

Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective
por: Zargaran, Marzieh, et al.
Publicado: (2021)

Moderate and severe plaque psoriasis: cost-of-illness study in Italy
por: Colombo, GL, et al.
Publicado: (2008)

Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
por: Gil, Fabio, et al.
Publicado: (2022)

Successful Treatment of a Reinfected Liver Graft Because of Receipt of a HCV-Positive Kidney
por: Azhari, Hassan, et al.
Publicado: (2020)

Cardiac Resynchronisation Therapy in Patients with Moderate to Severe Heart Failure in Germany: A Cost-Utility Analysis of the Additional Defibrillator
por: Hadwiger, Moritz, et al.
Publicado: (2020)

Cost Effectiveness of Different Treatment Strategies in the Treatment of Patients with Moderate to Severe Rheumatoid Arthritis in China
por: Wu, Bin, et al.
Publicado: (2012)

Teriparatide in the Treatment of Severe Postmenopausal Osteoporosis: A Cost-Utility Analysis
por: Taheri, Saeed, et al.
Publicado: (2019)

A Review of Respiratory Biologic Agents in Severe Asthma
por: Johnson, Nathaniel, et al.
Publicado: (2019)

Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain
por: Hidalgo-Vega, Álvaro, et al.
Publicado: (2015)

Treatment patterns, healthcare resource utilization, and costs in patients with moderate‐to‐severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study
por: Tada, Yayoi, et al.
Publicado: (2022)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
por: Johansson, Erin, et al.
Publicado: (2018)

Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure
por: Brusasco, Claudia, et al.
Publicado: (2021)

Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis
por: Jin, Joy Q, et al.
Publicado: (2023)

Chronic hepatitis E: an important entity for clinicians to be aware of
por: Congly, Stephen E., et al.
Publicado: (2022)

Remdesivir treatment for patients with moderate to severe COVID-19
por: HASANOĞLU, İmran, et al.
Publicado: (2022)

The real-world cost-effectiveness of bariatric surgery for the treatment of severe obesity: a cost–utility analysis
por: Lester, Erica L.W., et al.
Publicado: (2021)

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
por: Hansson-Hedblom, Amanda, et al.
Publicado: (2018)

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
por: Hendrix, Nathaniel, et al.
Publicado: (2018)

It is not always about gains: utilities and disutilities associated with treatment features in patients with moderate-to-severe psoriasis
por: Umar, Nasir, et al.
Publicado: (2012)

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
por: Colombo, Giorgio L, et al.
Publicado: (2011)

Effectiveness of face masks for reducing transmission of SARS-CoV-2: a rapid systematic review
por: Boulos, Leah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kb0tcr330cqfd32n12bumq58lv